ISRG — Intuitive Surgical, Inc.

Summary of ISRG Q2 2026 Earnings Call

1. Key Financial Results and Metrics

• Revenue: Increased by 19% to $2.89 billion, with recurring revenue accounting for 85% of total revenue.
• Non-GAAP Operating Margin: 42%.
• Non-GAAP Earnings Per Share: Rose 28% to $2.80, compared to $2.19 in Q2 2025.
• Total Procedures: Grew 16%, with da Vinci procedures up 15% and ION procedures up 36%.
• Installed Base: Global installed base of da Vinci and ION systems increased by 12% and 21%, respectively, totaling nearly 13,000 systems.
• Free Cash Flow: Increased by 71% to $1.8 billion in the first half of 2026.

2. Strategic Updates and Business Highlights

• Product Adoption: Strong growth in da Vinci 5 and SP platforms, with 468 da Vinci and 55 ION systems placed in Q2.
• International Growth: Notable growth in Europe (20%) and Asia (20%), with India showing strong momentum and Japan benefiting from new reimbursement policies.
• Extended Use Program: Announced plans to increase the number of uses for certain instruments to reduce costs, targeting broader adoption in cost-sensitive markets.
• Clinical Innovations: Continued development of robotic-assisted technologies, including a next-generation flexible robotic endoscope for gastrointestinal applications.

3. Forward Guidance and Outlook

• 2026 Procedure Growth: Maintaining guidance for da Vinci procedure growth at 13.5% to 15.5%, with expectations to be closer to the midpoint.
• Gross Profit Margin: Updated forecast for non-GAAP gross profit margin to 68%-69% of revenue.
• Operating Expenses: Expected growth in non-GAAP operating expenses to be between 11%-13%.
• Long-Term Opportunities: Continued focus on expanding into new clinical applications, particularly cardiac procedures and nipple-sparing mastectomies.

4. Bad News, Challenges, or Points of Concern

• US Procedure Growth Moderation: Growth in US da Vinci procedures moderated to 12%, attributed to deferred procedures and changes in patient coverage dynamics due to the expiration of ACA premium subsidies.
• China Market Challenges: Ongoing competitive pressures and pricing challenges in China, with lower tender activity and increased domestic competition.
• Bariatric Procedure Decline: Notable decline in da Vinci bariatric cases due to rising GLP-1 usage.
• Regulatory and Competitive Pressures: Engaging with provincial governments on charge code policy in China and navigating a dynamic policy environment.

5. Notable Q&A Insights

• Impact of ACA on Procedures: Management indicated that the moderation in US procedure growth could be partially due to ACA-related factors, but also noted the law of large numbers effect.
• Capital Environment: The US capital environment remains stable, with strong placements driven by interest in da Vinci 5, although some customers express caution regarding ACA enrollment trends.
• Extended Use Program Impact: Management refrained from quantifying the financial impact of the extended use program until further analysis is completed, but emphasized its strategic importance in lowering costs and expanding market access.
• Japan Reimbursement Changes: Positive reimbursement changes in Japan are expected to take time to translate into significant procedure growth, with cautious optimism for future adoption.

This summary encapsulates the financial performance, strategic initiatives, outlook, challenges, and insights from the Q&A session, providing a comprehensive overview of ISRG's current position and future direction.